Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, … editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
